Innate Pharma S.A.'s (EPA:IPH) Shift From Loss To Profit

We feel now is a pretty good time to analyse Innate Pharma S.A.'s (EPA:IPH) business as it appears the company may be on the cusp of a considerable accomplishment. Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. On 31 December 2025, the €172m market-cap company posted a loss of €49m for its most recent financial year. The most pressing concern for investors is Innate Pharma's path to profitability – when will it breakeven? We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Innate Pharma is bordering on breakeven, according to the 5 French Biotechs analysts. They expect the company to post a final loss in 2026, before turning a profit of €7.9m in 2027. The company is therefore projected to breakeven just over a year from today. How fast will the company have to grow each year in order to reach the breakeven point by 2027? Working backwards from analyst estimates, it turns out that they expect the company to grow 54% year-on-year, on average, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

Given this is a high-level overview, we won’t go into details of Innate Pharma's upcoming projects, but, take into account that typically a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.

View our latest analysis for Innate Pharma

One thing we would like to bring into light with Innate Pharma is it currently has negative equity on its balance sheet. Accounting methods used to deal with losses accumulated over time can cause this to occur. This is because liabilities are carried forward into the future until it cancels. These losses tend to occur only on paper, however, in other cases it can be forewarning.

Next Steps:

This article is not intended to be a comprehensive analysis on Innate Pharma, so if you are interested in understanding the company at a deeper level, take a look at Innate Pharma's company page on Simply Wall St. We've also compiled a list of pertinent aspects you should further research:

1. Historical Track Record: What has Innate Pharma's performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Innate Pharma's board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.